Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218367 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of pH Resections of GBM at VA
A Phase 1 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07218367: Clinical Trial Phase 1 study, sponsored by VA Office of Research and Development.
NCT07218367 is a Phase 1 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218367, a Phase 1 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Glioblastoma is an infiltrating tumor that is difficult to visualize in surgery and on standard images. A special pH (acid-base) related magnetic resonance imaging (MRI) has been developed to better see infiltrating tumor. In this safety study, the investigators will carry out increased levels of pH based resections of infiltrating tumor to assess the tolerability in VA populations.
Interventions
- PROCEDURE pH MRI based resection of GBM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2031-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218367
The ClinicalTrials.gov registry entry for NCT07218367 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pH MRI based resection of GBM is the first listed.
NCT07218367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07218367 about?
NCT07218367 is a clinical study titled "Phase I Trial of pH Resections of GBM at VA". Glioblastoma is an infiltrating tumor that is difficult to visualize in surgery and on standard images. A special pH (acid-base) related magnetic resonance imaging (MRI) has been developed to better see infiltrating tumor. In this safety study, the investigators will carry out increased levels of pH...
What is the current status of trial NCT07218367?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-07-01. Estimated completion is 2031-07-01.
What interventions are being tested in trial NCT07218367?
The interventions under investigation include: pH MRI based resection of GBM (PROCEDURE).
Who is sponsoring clinical trial NCT07218367?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.